Prelude Therapeutics Incorporated Common Stock (PRLD)

FairStock Score: 51/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach a clinical-stage oncology company with Graham's caution: without earnings, book value and cash burn become the anchors. Prelude Therapeutics is developing precision cancer medicines, but in fiscal FY2025, the year ended 2025-12-31, it reported revenue of $12.1 million and a net loss of $99.5 million; diluted EPS was -$1.29. That loss narrowed from $127.2 million and EPS of -$1.68 in FY2024, and revenue rose from $7.0 million, so the direction is better. In the latest filed quarter, fiscal Q2 2026 ended 2026-06-30, revenue was $5.7 million and net loss was $13.9 million, an improvement from the $19.7 million loss in fiscal Q3 2025. Still, the company has lost money in each of the last four years, so no Peter Lynch category fits; it is not yet a proven business.

In plain English: Prelude Therapeutics is a small clinical-stage company trying to develop new cancer medicines. It has no profits and spends more cash than it brings in, though its revenue has grown and its losses have shrunk recently. At $3.56, the stock is not supported by current earnings and looks expensive relative to today's financial numbers, so it depends mostly on future drug results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer